One lot of treprostinil injection is being recalled. Tresprostinil is a prostacyclin vasodilator used to treat patients with pulmonary arterial hypertension.
Par Pharmaceutical, part of Endo International, is recalling one lot of Treprostinil Injection 20 mg/20 mL. The product is being recalled because of the presence of silicone particulates in the product solution.
Treprostinil Injection is a prostacyclin vasodilator used to treat patients with pulmonary arterial hypertension and for patients who require transition from epoprostenol. The presence of silicone can result in local irritation or swelling at the injection site. If the silicone particulates reach the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain. To date, Par has not received any reports of adverse events related to the silicone particles.
The affected lot 57014 has an NDC number of 42023-206-01. It has an expiration date April 2024. The lot was distributed nationwide to wholesalers and hospitals from June 16, 2022, through Oct. 17, 2022.
Analysis Supports Initial Combination Therapy for Patients with PAH, Comorbidities
July 21st 2024Patients with pulmonary arterial hypertension and cardiopulmonary comorbidities are typically started on monotherapy, but new data suggest some patients would do well with initial combination therapy.
Read More
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More